FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.22
+3.68%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- -$1.04
- Revenue estimate
- $3.5M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$1.04
- EPS estimate
- -$1.02
- Revenue actual
- $3.8M
- Revenue estimate
- $3.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +43.2%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $31
- PT range
- $20 – $37
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$1.02 | -$1.04 | Miss -1.96% | $3.8M |
| May 7, 2026 | -$0.97 | -$1.01 | Miss -4.12% | $3.0M |
| Mar 18, 2026 | -$0.53 | $0.43 | Beat 181.44% | -$119.0K |
| May 8, 2025 | -$0.84 | -$0.86 | Miss -2.38% | $14.0K |
| Feb 28, 2025 | -$0.80 | -$0.90 | Miss -12.50% | — |
| Aug 8, 2024 | -$0.72 | -$0.63 | Beat 12.50% | — |
| May 9, 2024 | -$0.73 | -$0.66 | Beat 9.59% | $28.0K |
| Feb 29, 2024 | -$0.68 | -$0.77 | Miss -13.24% | — |
| Nov 9, 2023 | -$0.67 | -$0.24 | Beat 64.18% | $20.2M |
| Mar 15, 2023 | -$0.75 | -$0.84 | Miss -12.00% | $1.2M |
| Aug 11, 2022 | -$0.78 | -$0.87 | Miss -11.54% | $162.0K |
| May 12, 2022 | -$0.73 | -$0.82 | Miss -12.33% | $1.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026